Isabelle Iacono
Overview
Explore the profile of Isabelle Iacono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berthenet K, Aimontche E, El Mrini S, Briere J, Pion N, Iacono I, et al.
Sci Rep
. 2024 Feb;
14(1):3768.
PMID: 38355966
Neuroblastoma (NB) is the most common pediatric tumor and is currently treated by several types of therapies including chemotherapies, such as bortezomib treatment. However, resistance to bortezomib is frequently observed...
2.
Chicard M, Boyault S, Colmet Daage L, Richer W, Gentien D, Pierron G, et al.
Clin Cancer Res
. 2016 Jul;
22(22):5564-5573.
PMID: 27440268
Purpose: The tumor genomic copy number profile is of prognostic significance in neuroblastoma patients. We have studied the genomic copy number profile of cell-free DNA (cfDNA) and compared this with...
3.
Combaret V, Iacono I, Bellini A, Brejon S, Bernard V, Marabelle A, et al.
Cancer Med
. 2015 Feb;
4(4):540-50.
PMID: 25653133
New protocols based on ALK-targeted therapy by crizotinib or other ALK-targeting molecules have opened for the treatment of patients with neuroblastoma (NB) if their tumors showed mutation and/or amplification of...
4.
Combaret V, Iacono I, Brejon S, Schleiermacher G, Pierron G, Couturier J, et al.
Cancer Genet
. 2012 Dec;
205(12):657-64.
PMID: 23265803
In cases of neuroblastoma, recurring genetic alterations--losses of the 1p, 3p, 4p, and 11q and/or gains of 1q, 2p, and 17q chromosome arms--are currently used to define the therapeutic strategy...
5.
Combaret V, Brejon S, Iacono I, Schleiermacher G, Pierron G, Ribeiro A, et al.
Pediatr Blood Cancer
. 2011 Mar;
56(5):757-61.
PMID: 21370407
Background: Retrospective studies have demonstrated the prognostic impact of genomic profiles in neuroblastoma (NB). Segmental chromosome alterations have been found useful for identifying tumors with a high risk of relapse....
6.
Chargui J, Combaret V, Scaglione V, Iacono I, Peri V, Valteau-Couanet D, et al.
J Immunother
. 2010 Jun;
33(6):591-8.
PMID: 20551838
Gamma/delta T cells (Vgamma9delta2) contribute to innate immunity and exert natural cytotoxicity against a variety of tumors. Using a synthetic phosphoantigen (Bromohydrin Pyrophosphate, BrHPP), we amplified Vgamma9delta2 T cells in...
7.
Combaret V, Hogarty M, London W, McGrady P, Iacono I, Brejon S, et al.
Pediatr Blood Cancer
. 2009 Mar;
53(3):329-31.
PMID: 19301388
Background: MYCN oncogene amplification has been defined as the most important prognostic factor for neuroblastoma (NB), the most common solid extracranial neoplasm in children. High copy numbers are strongly associated...
8.
Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A
Mol Cancer
. 2008 Jun;
7:50.
PMID: 18534018
Background: Bortezomib, a specific and selective inhibitor of the 26S proteasome with antitumor activity against a wide range of malignancies, has been approved for the treatment of relapsed or refractory...
9.
Combaret V, Bergeron C, Noguera R, Iacono I, Puisieux A
J Clin Oncol
. 2005 Nov;
23(34):8919-20.
PMID: 16314658
No abstract available.
10.
Krause A, Combaret V, Iacono I, Lacroix B, Compagnon C, Bergeron C, et al.
Cancer Lett
. 2005 Jun;
225(1):111-20.
PMID: 15922863
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood and the third most common pediatric cancer. Although numerous factors including patient age, disease stage and genetic abnormalities have...